Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;116(1):41-47.
doi: 10.1007/s12185-022-03361-5. Epub 2022 May 14.

Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases

Katsutsugu Umeda  1
Affiliations
Review

Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases

Katsutsugu Umeda. Int J Hematol. 2022 Jul.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) can be curative for a variety of non-malignant diseases (NMDs) as well as hematological malignancies. However, there are several fundamental differences between HCT for NMDs and hematological malignancies, which may necessitate the use of alternative HCT strategies. For example, these diseases differ in the intensity of conditioning regimen sufficient to improve disease. In addition, patients with NMDs are at higher risk of graft failure or mixed chimerism following HCT, and gain no or little survival benefit from graft-versus-host disease. Because more than 80% of patients with NMDs become long-term survivors, greater attention has been paid to late adverse effects and decreased of quality of life after HCT. This review addresses several unresolved issues in allogeneic HCT for patients with NMDs, such as (1) stem cell source, (2) conditioning regimen, (3) use of serotherapy or low-dose irradiation, and (4) therapeutic intervention for mixed chimerism. Resolving these issues may improve transplant outcomes in patients with NMDs.

Keywords: Hematopoietic cell transplantation; Mixed chimerism; Non-malignant disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364:156–62. - PubMed - DOI
    1. Lankester AC, Albert MH, Booth C, et al. EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant. 2021;56:2052–62. - PubMed - PMC - DOI
    1. Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116:5824–31. - PubMed - DOI
    1. Chiesa R, Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol. 2012;8:255–66. - PubMed - DOI
    1. Kato S, Yabe H, Takakura H, et al. Hematopoietic stem cell transplantation for inborn errors of metabolism: a report from the research committee on transplantation for inborn errors of metabolism of the Japanese ministry of health, labour, and welfare and the working group of the japan society for hematopoietic cell transplantation. Pediatr Transplant. 2016;20:203–14. - PubMed - DOI

MeSH terms

LinkOut - more resources